JP2013523705A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523705A5
JP2013523705A5 JP2013501932A JP2013501932A JP2013523705A5 JP 2013523705 A5 JP2013523705 A5 JP 2013523705A5 JP 2013501932 A JP2013501932 A JP 2013501932A JP 2013501932 A JP2013501932 A JP 2013501932A JP 2013523705 A5 JP2013523705 A5 JP 2013523705A5
Authority
JP
Japan
Prior art keywords
ester
physiologically acceptable
formula
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013501932A
Other languages
English (en)
Japanese (ja)
Other versions
JP6023696B2 (ja
JP2013523705A (ja
Filing date
Publication date
Priority claimed from GBGB1005518.4A external-priority patent/GB201005518D0/en
Priority claimed from GBGB1005522.6A external-priority patent/GB201005522D0/en
Application filed filed Critical
Priority claimed from PCT/GB2011/000497 external-priority patent/WO2011121305A2/en
Publication of JP2013523705A publication Critical patent/JP2013523705A/ja
Publication of JP2013523705A5 publication Critical patent/JP2013523705A5/ja
Application granted granted Critical
Publication of JP6023696B2 publication Critical patent/JP6023696B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013501932A 2010-03-31 2011-03-31 ミョウバンアジュバントおよびミョウバンアジュバント化ワクチンの保存方法 Active JP6023696B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1005518.4A GB201005518D0 (en) 2010-03-31 2010-03-31 Preservation of alum-adjuvanted vaccines
GB1005518.4 2010-03-31
GB1005522.6 2010-03-31
GBGB1005522.6A GB201005522D0 (en) 2010-03-31 2010-03-31 Method for preserving alum-adjuvanted vaccines
PCT/GB2011/000497 WO2011121305A2 (en) 2010-03-31 2011-03-31 Method for preserving alum adjuvants and alum-adjuvanted vaccines

Publications (3)

Publication Number Publication Date
JP2013523705A JP2013523705A (ja) 2013-06-17
JP2013523705A5 true JP2013523705A5 (enExample) 2014-04-24
JP6023696B2 JP6023696B2 (ja) 2016-11-09

Family

ID=43971221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013501932A Active JP6023696B2 (ja) 2010-03-31 2011-03-31 ミョウバンアジュバントおよびミョウバンアジュバント化ワクチンの保存方法

Country Status (13)

Country Link
US (1) US9101607B2 (enExample)
EP (1) EP2552410B1 (enExample)
JP (1) JP6023696B2 (enExample)
KR (1) KR101819250B1 (enExample)
CN (1) CN102892409B (enExample)
AU (1) AU2011234268B2 (enExample)
BR (1) BR112012025044A2 (enExample)
CA (1) CA2795050C (enExample)
DK (1) DK2552410T3 (enExample)
ES (1) ES2708989T3 (enExample)
GB (1) GB2499480A (enExample)
HU (1) HUE042330T2 (enExample)
WO (1) WO2011121305A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102892424B (zh) 2010-03-31 2015-04-01 稳定性科技有限公司 病毒颗粒的稳定
EP2552478B1 (en) 2010-03-31 2016-12-21 Stabilitech Ltd. Excipients for stabilising viral particles
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
WO2015157637A1 (en) * 2014-04-11 2015-10-15 Surmodics Ivd, Inc. Compositions and methods for in vitro diagnostic tests including zwitterionic solubilization reagent
GB201406569D0 (en) * 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
CN113750228B (zh) * 2021-09-25 2024-02-20 大连理工大学 一种冷冻保护剂在铝佐剂中的应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927208A (en) 1973-05-14 1975-12-16 Rit Rech Ind Therapeut Live bovine adenovirus vaccines, preparation thereof and method of vaccination using them
US4631189A (en) 1980-03-10 1986-12-23 Da Vinci Laboratories, a division of FoodScience Corporation N,N-dimethylglycine and use in immune response
JPS6013718A (ja) * 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst B型肝炎ワクチン
JPS60193925A (ja) 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
JPS61189228A (ja) 1985-02-19 1986-08-22 Nippon Sekijiyuujishiya 血液凝固第8因子製剤の製法
US4950596A (en) 1985-03-04 1990-08-21 The Dow Chemical Company Stabilization of intracellular enzymes
JPS6238173A (ja) 1985-08-13 1987-02-19 三菱レイヨン株式会社 抗血液凝固剤
US5169758A (en) 1986-05-02 1992-12-08 Boehringer Mannheim Gmbh Stabilized, NAD(P)H-dependent, soluble nitrate reductase, a process for the preparation thereof and a reagent containing it
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
DE3782737T3 (de) * 1987-08-21 1999-05-20 Imcera Group Inc., Northbrook, Ill. Stabilisierung von Wachstumshormonen.
GB8826429D0 (en) 1988-11-11 1988-12-14 Univ Leeds Ind Service Ltd Enzyme stabilisation systems
DE69032102T2 (de) 1989-08-15 1998-06-25 Massachusetts Inst Technology Stabilisierte impfstoffzusammensetzungen
AU650045B2 (en) 1990-09-12 1994-06-09 Lifecell Corporation Method and apparatus for cryopreparation dry stabilization and rehydration of biological suspensions
ZA936095B (en) 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
WO1995011700A1 (en) * 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
PT2275119E (pt) 1995-07-27 2013-11-21 Genentech Inc Formulação de proteína liofilizada isotónica estável
GB9521806D0 (en) 1995-10-25 1996-01-03 Cortecs Ltd Preservation methods
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
US6656734B1 (en) 1997-07-01 2003-12-02 Transgene S.A. Compositions for the delivery of polynucleotides to cells
AU5459698A (en) 1997-11-26 1999-06-15 Universal Preservation Technologies, Inc. Preservation of sensitive biological samples by vitrification
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
DK1133316T3 (da) 1998-11-16 2009-05-25 Introgen Therapeutics Inc Adenovirus-formulering til genterapi
AUPQ347199A0 (en) 1999-10-15 1999-11-11 Csl Limited Novel polypeptide fragments
MXPA02012039A (es) * 2000-06-08 2003-06-06 Powderject Vaccines Inc Composiciones en polvo.
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US20040110267A1 (en) 2000-12-15 2004-06-10 Stratagene Room temperature stable competent cells
AU2002302814A1 (en) 2001-06-08 2002-12-23 Powderject Vaccines, Inc. Spray freeze-dried compositions
US7101693B2 (en) 2001-09-07 2006-09-05 Brigham Young University Plasticized hydrophilic glasses for improved stabilization of biological agents
JP4936618B2 (ja) * 2001-09-21 2012-05-23 株式会社ノエビア 微細エマルション組成物
US20040161776A1 (en) * 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
EP3210624A1 (en) 2002-02-27 2017-08-30 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
EP1539244A1 (en) 2002-06-27 2005-06-15 Novo Nordisk A/S Use of dimethyl sulfone as isotonicity agent
WO2004007537A2 (en) 2002-07-10 2004-01-22 Transgene S.A. Modified adenoviral fiber with ablated to cellular receptors
WO2004035818A1 (en) 2002-10-21 2004-04-29 Biotage Ab Use of osmolytes to heat stabilise luciferase and/or apyrase
JP2006521084A (ja) 2002-12-10 2006-09-21 シェーリング−プラウ・リミテッド イヌranklならびにイヌranklを調製および使用するための方法
US20060247167A1 (en) 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
US7642077B2 (en) 2003-12-08 2010-01-05 Genencor International, Inc. Biocomposite comprising co-precipitate of enzyme, silicate and polyamine
EP1711619A4 (en) 2003-12-30 2007-04-11 Virumar Pituach Tarkivin Ltd INTEGRATED VIRUS COMPLEXES, METHOD FOR THE MANUFACTURE THEREOF, VACCINES CONTAINING THEM AND METHOD FOR THE USE THEREOF
BRPI0508440A (pt) 2004-03-03 2007-07-24 Revance Therapeutics Inc composições e métodos para diagnóstico tópico e transporte terapêutico
US20060058238A1 (en) 2004-09-15 2006-03-16 Lee Laurent-Applegate Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
KR101341359B1 (ko) 2004-10-01 2013-12-13 램스코르 인코포레이티드 편리하게 이식가능한 서방형 약물 조성물
US20060210557A1 (en) 2005-01-28 2006-09-21 Donna Luisi Stabilized liquid polypeptide formulations
GB0502661D0 (en) 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
TWI398272B (zh) 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
WO2006127150A2 (en) 2005-04-08 2006-11-30 Argos Therapeutics, Inc. Dendritic cell compositions and methods
US20090155351A1 (en) * 2005-10-04 2009-06-18 Alk-Abello A/S Solid Vaccine Formulation
KR101357685B1 (ko) 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
CA2631292C (en) 2005-11-30 2014-05-06 International Institute Of Cancer Immunology, Inc. Derivatised wt1 cancer antigen peptides and their use
CA2631714C (en) 2005-12-02 2014-09-16 Novartis Ag Nanoparticles for use in immunogenic compositions
WO2007095337A2 (en) 2006-02-15 2007-08-23 Imclone Systems Incorporated Antibody formulation
ES2286951B1 (es) * 2006-05-26 2008-10-01 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas bioadhesivas para la administracion de moleculas biologicamente activas.
AU2007317347B2 (en) 2006-11-03 2014-02-06 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
CA2681567C (en) 2007-03-22 2016-07-19 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
US7879805B2 (en) * 2007-06-01 2011-02-01 Acologix, Inc. High temperature stable peptide formulation
WO2009015343A2 (en) * 2007-07-25 2009-01-29 Bioe, Inc. Differentiation of multi-lineage progenitor cells to chondrocytes
US20090123436A1 (en) 2007-11-08 2009-05-14 Surmodics, Inc. Cryopreservative compositions and methods
US20110212127A1 (en) 2008-09-24 2011-09-01 Stabilitech Ltd. Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine
US20110236412A1 (en) 2008-09-24 2011-09-29 Stabilitech Ltd. Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine
CN101670104A (zh) 2009-09-24 2010-03-17 浙江大学 一种含人参皂甙的油佐剂及其制备方法
CN102892424B (zh) 2010-03-31 2015-04-01 稳定性科技有限公司 病毒颗粒的稳定

Similar Documents

Publication Publication Date Title
JP2013523705A5 (enExample)
JP2013523704A5 (enExample)
RU2641198C3 (ru) Композиции glp-1 пептидов и их получение
EA201400679A1 (ru) Композиция сухого порошка производного азола для ингаляции
WO2013177172A3 (en) Herpesvirus compositions and related methods
PE20140845A1 (es) Formulaciones parenterales de vacunas contra los norovirus
RU2015118581A (ru) Лиофилизированные препараты мелфалана флуфенамида
Newcomer et al. Approved and experimental countermeasures against pestiviral diseases: bovine viral diarrhea, classical swine fever and border disease
NZ630219A (en) Lyophilization of synthetic liposomal pulmonary surfactant
JP2013542263A5 (enExample)
JP6023696B2 (ja) ミョウバンアジュバントおよびミョウバンアジュバント化ワクチンの保存方法
CN106063933A (zh) 通用疫苗冻干保护剂及其应用
PE20100365A1 (es) Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
RU2016136327A (ru) Композиции на основе мелатонина для парентерального введения
JP6235614B2 (ja) 注射用hpph凍結乾燥粉末注射剤およびその製造方法
JP2018538308A5 (enExample)
AR087346A1 (es) Formulaciones de compuestos de tiofeno
CN103505723B (zh) 狂犬疫苗冻干制剂的制备方法
Asim et al. Effect of various stabilizers on titre of lyophilized live-attenuated Peste des petits ruminants (PPR) vaccine.
RU2016115374A (ru) Фармацевтические композиции, содержащие антибактериальные агенты
AR089737A1 (es) Procedimiento de formulacion de una vacuna que contiene al menos dos antigenos susceptibles de adsorberse sobre el oxi-hidroxido de aluminio
JP2014515371A5 (enExample)
RU2016101248A (ru) Лиофилизированные препараты бендамустина гидрохлорида
CN104940149A (zh) 一种复方氨林巴比妥注射冻干粉针剂及其制备方法
RU2015129081A (ru) Гелевые композиции